Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment
Late-Breaking Presentation at American Academy of Dermatology 2024
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Protagonist Therapeutics Reports Granting of Inducement Awards
Takeda wagers $300M on Protagonist’s PhIII rare disease drug
Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
Protagonist to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024